Upadacitinib for Treatment-Resistant Urticarial Vasculitis: A Case Study and Therapeutic Insight

Francesca Falcinelli; Edoardo Conticini; Luca Cantarini; Bruno  Frediani; Pietro Rubegni; Laura Calabrese

doi:10.5826/dpc.1502a5139

Upadacitinib for Treatment-Resistant Urticarial Vasculitis: A Case Study and Therapeutic Insight

Authors

Francesca Falcinelli Department of Medical, Surgical and Neurological Science, Dermatology Section, University of Siena, S. Maria alle Scotte Hospital, Siena, Italy https://orcid.org/0000-0002-3149-8695
Edoardo Conticini Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Italy
Luca Cantarini Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Italy
Bruno Frediani Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Italy
Pietro Rubegni Dermatology Unit and Skin Bank, Department of Medical, Surgical and Neurosciences, Siena University Hospital, Siena – Italy
Laura Calabrese Dermatology Unit and Skin Bank, Department of Medical, Surgical and Neurosciences, Siena University Hospital, Siena – Italy; Institute of Dermatology, Catholic University of the Sacred Heart, Rome, Italy

Keywords:

urticarial vasculitis, upadacitinib, jak-inhibitors, Janus Kinase Inhibitors

References

Marzano AV, Maronese CA, Genovese G, et al. Urticarial vasculitis: Clinical and laboratory findings with a particular emphasis on differential diagnosis. J Allerg Clin. 2022; 149: 1137–1149. DOI:10.1016/j.jaci.2022.02.007.

Mohamed MF, Bhatnagar S, Parmentier JM, et al. Upadacitinib: Mechanism of action, clinical, and translational science. Clinic Transl Sci. 2024; 17: e13688. DOI:10.1111/cts.13688.

Mansouri P, Mozafari N, Chalangari R, Martits‐Chalangari K. Efficacy of oral tofacitinib in refractory chronic spontaneous urticaria and urticarial vasculitis. Dermatol Ther. 2022; 35. DOI:10.1111/dth.15932.

Zhu K-J, Yang P-D, Xu Q. Tofacitinib Treatment of Refractory Cutaneous Leukocytoclastic Vasculitis: A Case Report. Front Immunol. 2021; 12: 695768. DOI:10.3389/fimmu.2021.695768

Rathore U, Thakare DR, Patro P, et al. A systematic review of clinical and preclinical evidences for Janus kinase inhibitors in large vessel vasculitis. Clin Rheumatol 2022; 41: 33–44. DOI:10.1007/s10067-021-05973-4.

Ebata A, Ogawa-Momohara M, Fukaura R, et al. Increased Janus kinase activation in cutaneous vasculitis. J Am Acad Dermatol. 2024; 90: 627–629. DOI:10.1016/j.jaad.2023.10.056.